menu transformed by yes Another future made better by Ionis innovation. Transformative technology We are the leader in discovering and developing RNA-targeted therapeutics. Our efficient, broadly applicable drug discovery platform, called antisense technology, can treat illnesses where no other therapeutic approaches have proven effective or ever existed. Learn more about our Ionis Innovations Once in a lifetime breakthroughs again and again We look to patients and their loved ones to help us better understand what it means to live with disease, so we can focus our efforts where we believe we can make the most meaningful contribution to improve lives. See who inspires us A perpetual and efficient innovation machine Our drug discovery platform has served as a springboard for drug discovery and realized hope for patients with unmet needs. Our broad, diverse pipeline has more than 40 first-in-class and/or best-in-class medicines designed to treat a broad range of diseases. Review our pipeline Press releases View all press releases NOV 18 Ionis initiates Phase 3 clinical program of donidalorsen in patients with hereditary angioedema.cls-orange{fill:none;stroke:#ea7425;stroke-miterlimit:10;}orange-arrow NOV 12 Ionis’ antisense therapies to be featured at the American Heart Association (AHA) Scientific Sessions 2021.cls-orange{fill:none;stroke:#ea7425;stroke-miterlimit:10;}orange-arrow NOV 07 Phase 2 study results of Ionis’ novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meeting.cls-orange{fill:none;stroke:#ea7425;stroke-miterlimit:10;}orange-arrow Careers From the moment of our founding, we knew we could transform the biopharmaceutical industry. We had the people, the science and the unwavering commitment to bring about a new approach to drug discovery and development that would deliver innovative treatments to patients where no others had proven effective or ever existed. If you have this same commitment to be a force for life and feel that Ionis is right for you, we want to hear from you. Join our team Please be aware of employment scams using Ionis’ name and the names of Ionis employees to lure unsuspecting people into providing highly confidential and personal information. For more information click here to read more. latest updates Topline results of Phase 2 clinical study support continued development of Cimdelirsen designed to treat uncontrolled acromegaly Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology Ionis to hold second quarter financial results webcast ©1989 – 2021 Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics® is a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. Contact Suppliers Legal Notice Privacy Policy Social Media Policies